EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants

Michael Watkins iD, Yali Zhu, David C Griffith iD, Jeffery S Loutit, David Margolis, Peidi Gu

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01288-24 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Michael Watkins und 5 weiteren Autor:innen. Beteiligte Einrichtung: Brii Biosciences Inc., Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Peptides, Cyclic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | Biomedical Advanced Research and Development Authority (BARDA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRII-693 is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic for infections caused by drug-resistant gram-negative pathogens. This single-center, randomized, double-blind, placebo-controlled phase 1 study investigated the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of BRII-693 in 104 healthy participants. In single-dose cohorts, 10–400 mg of BRII-693 was evaluated in eight participants (six active; two placebo) per cohort. In the 7-day repeat-dose cohorts, 100–200 mg of BRII-693 was evaluated in eight participants (six active; two placebo) per cohort. In two 14-day repeat-dose cohorts, 150 mg of BRII-693 was evaluated in 12 participants (10 active, two placebo) each of non-Chinese and Chinese descent. No participant reported a severe or serious adverse event (AE) or an AE leading to death. Across all cohorts and for non-Chinese and Chinese participants, most AEs were mild. C max and area under the concentration-time curve (AUC) increased in a dose-proportional manner over the dose range of single- and repeat-dosing. Mean t 1/2 was 2.58–4.37 hours and generally similar across single doses. An accumulation of exposure was observed following multiple doses with an accumulation ratio of 1.5 to 1.7 which was within the expected 1.3 to 2.5 range at steady state. Mean total clearance (CL) was similar between single and multiple dose administration, suggesting time-independent pharmacokinetics (PK). PK exposure was statistically equivalent between non-Chinese and Chinese participants. This phase 1 study demonstrates a favorable safety, tolerability, and PK profile of BRII-693 in healthy non-Chinese and Chinese participants. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04808414 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsPeptides, CyclicHumansMaleFemaleAdultDouble-Blind MethodMiddle AgedHealthy VolunteersYoung AdultArea Under Curve

Stichwörter der Autor:innen

antibioticpharmacokineticsphase 1safety

Substanzen

Anti-Bacterial AgentsPeptides, Cyclic

Autor:innen und Institutionen

  • Brii Biosciences Inc., Durham, North Carolina, USA.
  • Qpex Biopharma Inc., San Diego, California, USA.

ORCID-Profile: Michael Watkins, David C Griffith

Förderung

  • HHS | Biomedical Advanced Research and Development Authority (BARDA)

Zitieren

APA

Watkins, M., Zhu, Y., Griffith, D. C., Loutit, J. S., Margolis, D., & Gu, P. (2025). Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01288-24

Vancouver

Watkins M, Zhu Y, Griffith DC, Loutit JS, Margolis D, Gu P. Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01288-24

BibTeX
@article{Watkins2025,
  author = {Watkins, Michael and Zhu, Yali and Griffith, David C and Loutit, Jeffery S and Margolis, David and Gu, Peidi},
  title = {Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01288-24}
}
Kostenlos starten →